Colgate-Palmolive or L'Oréal: which stock to buy?
2026-07-21 · By Lubin Danilo, founder of Lubin Investment
Analyze a stock on Lubin Investment
Colgate-Palmolive and L'Oréal both score 9 out of 10 on my quality checklist: profitable, low debt, strong cash generators. But L'Oréal trades roughly 45% more expensive than Colgate-Palmolive for barely higher growth. Here is why that price gap deserves scrutiny before you invest.
Two brands you cross paths with every day without thinking about it
A tube of Colgate toothpaste in the bathroom, a bottle of L'Oréal Paris shampoo in the shower: these two companies have been part of the background for so long that we forget they are publicly traded, let alone worth comparing. Colgate-Palmolive means toothpaste, soap, everyday household products, sold in more than 200 countries. L'Oréal means beauty in every form: cosmetics, hair care, fragrances, dermatology, with brands ranging from L'Oréal Paris to Lancôme.
Two companies, one broad sector (household and personal products), and the same question before investing in either: is it a good business, and at what price? Two questions I always judge separately, never mixed.
The quality match: two 9-out-of-10 scores, for different reasons
| Criterion | Colgate-Palmolive (CL) | L'Oréal (OR.PA) |
|---|---|---|
| Quality score | 9/10 | 9/10 |
| Net margin | 10.0% | 13.9% |
| Sales growth (5y) | 4.3%/yr | 4.8%/yr |
| Cash-per-share growth (5y) | 10.7%/yr | 12.9%/yr |
| Free cash flow margin | 17.3% | 16.3% |
| Return on capital (Cash ROCE) | 54.1% | 31.1% |
| Net debt / FCF | 1.85 yr | 0.29 yr |
| Current P/FCF | ≈20.3x | ≈28.5x |
| Market cap | ≈$71B | ≈$204B |
Both companies fail the same criterion: sales growth, below the 10% per year my filter requires (4.3% for Colgate, 4.8% for L'Oréal). Normal for mature multinationals selling products already present in nearly every household in the developed world: growth can no longer come from volume alone, it comes from price, product mix (selling more premium products), and winning new markets.
Where the two diverge is how they turn sales into cash available to shareholders. Colgate-Palmolive posts a Cash ROCE of 54.1%, versus 31.1% for L'Oréal: for every dollar of capital tied up in the business, Colgate pulls out more cash each year. Part of the gap comes from the nature of the business: toothpaste and soap are simple products to manufacture at massive scale with relatively light industrial equipment, while L'Oréal invests heavily in research, brand marketing, and premium distribution (department store counters, dermatologist partnerships), a more capital-hungry model that justifies significantly higher selling prices.
Debt tells a different story too
Colgate-Palmolive carries net debt equal to 1.85 years of free cash flow, versus just 0.29 years for L'Oréal. That is not a red flag (my filter counts "healthy" up to 3 years), but the gap deserves context: Colgate has run buyback programs and investments funded by low-cost debt in recent years, a deliberate capital allocation choice as long as the cost of that debt stays below the return it generates. L'Oréal, on the other hand, remains a near debt-free fortress, a more conservative choice that leaves enormous room to fund acquisitions or brand buyouts when an opportunity arises.
Two very concrete growth stories
The first quarter of 2026 illustrates two different growth engines well. Colgate-Palmolive posted adjusted earnings per share of $0.97, beating analyst expectations for the fourth straight quarter, driven by 8.4% year-over-year sales growth and free cash flow up 27.9% to $609 million. The company also raised its quarterly dividend to $0.53, the 63rd consecutive annual increase: a rare signal of financial discipline (even though my quality filter deliberately does not include dividends as a criterion), sustained even through macroeconomic slowdowns.
Colgate's real challenge, flagged by analysts themselves, is its growing reliance on price increases rather than volume to grow revenue, an increasingly difficult exercise in emerging markets (45% of its sales), where more price-sensitive consumers are pushing back harder. Rising resin costs (a key packaging raw material), worsened by geopolitical tensions around Iran disrupting some supply chains, add further pressure on margins. These are real headwinds, not theoretical risks.
L'Oréal, for its part, posted organic growth of 7.6% in the first quarter of 2026 (6.7% adjusted for a one-off IT impact), faster than the overall global beauty market (around 4%), and is gaining market share across every region and division. China, long a worry for the entire luxury and beauty sector, is showing signs of recovery with high single-digit growth in the first quarter, even though travel retail there remains weak. L'Oréal remains the number one beauty player in China and keeps investing there, including a joint lab with Shanghai's Huashan Hospital for dermatological research, opened in November 2025.
L'Oréal's real moat, beyond its brands, is its ability to turn scientific research into products that justify a premium price: its BIG BANG Beauty Tech innovation programme has produced more than 80 collaborations with startups, and two of its recent innovations (the AirLight Pro hair dryer and Lancôme's Nano-Resurfacer) were named among the year's best inventions by Time magazine. That kind of continuously renewed innovation is what lets L'Oréal sell a shampoo or cream for several times the price of a basic product, and justify it to the consumer.
The price: where the gap becomes the real story
This is where the comparison matters most. L'Oréal trades at a P/FCF of about 28.5 times its free cash flow, versus about 20.3 times for Colgate-Palmolive, a premium of roughly 40 to 45% for L'Oréal. For cash-per-share growth barely higher over 5 years (12.9% versus 10.7% per year), that is a valuation gap worth questioning rather than accepting by reflex because "L'Oréal is the better brand."
To place this P/FCF in context, I never compare it only between the two companies: I first place it against each one's own history. Colgate-Palmolive's current P/FCF sits around the 39th percentile of its past five years: it has traded more expensive than today roughly 6 times out of 10 over that period, neither a low nor a high. For L'Oréal, this data point is unfortunately not available in my history (long series are often missing outside US markets): I degrade gracefully rather than invent a number, and rely only on the reasonable-buy-price comparison below for this stock.
My model puts Colgate-Palmolive's reasonable buy price around $65, versus a stock trading around $89 to $90 in mid-2026, roughly 37% above that entry point. For L'Oréal, the reasonable buy price sits around €217, versus a share price around €382, nearly 75% above. Both stocks are expensive relative to my target price, but L'Oréal significantly more so, which is not illogical given its currently stronger organic growth and its dominant position in China starting to pay off again, but it leaves little room for error if that momentum slows.
The real debate between the two
If you have to choose: Colgate-Palmolive gives you a more profitable cash machine per dollar invested, slightly higher but well-managed debt, a dividend raised for 63 straight years, at a price less disconnected from my fair value estimate. The risk is its reliance on price increases in emerging markets that are pushing back harder. L'Oréal offers you organic growth faster than its market, a nearly debt-free balance sheet, and a genuine scientific innovation moat, but at a price that already prices in a lot of good news, especially around the Chinese recovery. Neither is a bad choice: the real question is how much you are willing to pay for the extra growth and brand story L'Oréal offers.
My method, in one sentence
I never ask "which is the better brand," I ask "which is the better business, at what price." That strict separation between quality and valuation is exactly why I built my analysis site, with full profiles for Colgate-Palmolive and L'Oréal.
- Colgate-Palmolive and L'Oréal each pass 9 out of 10 on my quality checklist, both limited by sales growth below 10%/year.
- Colgate-Palmolive: Cash ROCE of 54.1%, dividend raised for 63 consecutive years, but reliant on price increases in pushier emerging markets.
- L'Oréal: 7.6% organic growth in Q1 2026 (faster than the global beauty market), nearly debt-free balance sheet, strong recovery in China.
- L'Oréal trades roughly 40 to 45% more expensive than Colgate-Palmolive on P/FCF, for barely higher cash-per-share growth.
- Both stocks trade above my reasonable buy price (Colgate ≈37% above, L'Oréal ≈75% above): neither is currently a bargain.
FAQ
Are Colgate-Palmolive and L'Oréal in the same sector?
Broadly yes (household and personal products), but Colgate focuses on everyday hygiene while L'Oréal focuses on beauty and premium cosmetics.
Why is L'Oréal more expensive than Colgate-Palmolive?
The market grants it a premium for faster organic growth, its dominant China position, and its scientific innovation moat. The question is whether that premium (40 to 45% on P/FCF) is justified.
Which of the two pays the better dividend?
Colgate-Palmolive has raised its dividend for 63 consecutive years, a rare signal of financial discipline. L'Oréal also pays a dividend, but my analysis focuses on free cash flow rather than dividend yield alone.
Should you buy either stock today?
Both trade above my reasonable buy price right now. This is not personalized investment advice, do your own research before deciding.
Analyze a stock on Lubin Investment
About the author
Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).